NCT01690871 - A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | Biotech Hunter

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Malignant PEComa (Perivascular Epithelioid Cell Tumors)

Interventions

DRUG

BEZ235

Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.

Trial Locations (1)

08025

Novartis Investigative Site, Barcelona